[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spine-fusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spine-fusion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,77,104,128,168,197,230,252,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100496585","phase-4-the-effect-of-zolpidem-on-outcomes-following-lumbar-spine-fusion-100496585",false,"NCT05746143","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion: A Randomized Control Trial","Inclusion Criteria:\n\n* degenerative lumbar disease\n* age of 18-75\n* undergoing open primary one- to three-level lumbar fusion\n\nExclusion Criteria:\n\n* currently use a sleep aid nightly\n* diagnosed with insomnia or sleep apnea\n* history of delirium with opiates or zolpidem\n* allergic to opiates or zolpidem\n* had previous lumbar spine surgery\n* undergoing minimally invasive lumbar fusion,\n* undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy","ALL","18 Years","75 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.",[27,28,29,30],"Spine Fusion","Lumbar Spine Degeneration","Pain, Postoperative","Lumbar Spine Spondylosis",[32,33,34],"Lumbar Spine Fusion","Zolpidem","Postoperative Outcomes","RECRUITING","2026-04-29",{"date":38,"type":39},"2026-05-01","ACTUAL",{"date":41,"type":39},"2022-02-01",{"date":43,"type":21},"2030-12-31",{"name":45,"class":46},"University of Southern California","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100467503","personalized-perioperative-analgesia-platform-ppap-for-pediatric-spine-fusion-surgery-sirb-100467503","NCT05367609","Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB)","PPAP Spine","Inclusion Criteria:\n\n* Children ages 10 to 21\n* ASA physical status 1 to 3\n* Undergoing Posterior-Lateral Spinal Fusion\n* Receives in-patient opioids\n* Prescribed opioids at discharge\n\nExclusion Criteria:\n\n* Serious illness\n* Preoperative severe pain\n* Preoperative opioid use or misuse","10 Years","21 Years",{"count":58,"type":21},300,[60],"NA","The purpose of this collaborative CTSA application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in children undergoing painful surgery.",[63,27],"PPAP",[63,65,66],"Pediatric","Spine Fusion Surgery","2026-04-07",{"date":69,"type":39},"2026-04-13",{"date":71,"type":39},"2022-09-20",{"date":73,"type":21},"2027-10-30",{"name":75,"class":46},"Senthil Sadhasivam",5,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100414686","post-marketing-study-of-magnetos-easypack-putty-standalone-compared-to-demineralized-bone-matrix-or-fibers-mixed-with-autograft-in-patients-undergoing-posterolateral-lumbar-fusion-100414686","NCT04679844","Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion","A Prospective, Randomized, Multi-Center Study to Assess the Safety and Performance of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers (DBX or Grafton) Mixed With Local Autograft in Patients Undergoing One to Two-Level Instrumented Posterolateral Lumbar\u002FThoracolumbar Fusion (PLF)","PROOF","Inclusion Criteria:\n\n* Patient is able to read\u002Fbe read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.\n* Male or female patient ≥ 18 years old.\n* Patients with segmental mechanical spinal instability requiring arthrodesis surgery.\n\nInstability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar\u002Fthoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:\n\n1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion\u002Fextension radiographs),\n2. decreased disc height by \\> 2 mm, but dependent upon the spinal level\n3. Grade II or more listhesis\n4. TLICS equal or greater than 5\n5. Unstable burst fracture\n\n   * Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.\n\nExclusion Criteria:\n\n* Requires \\> two-level fusion or expected to need secondary intervention within one year following surgery.\n* Had prior PLF fusion or attempted PLF fusion at the involved levels.\n* Had previous decompression at the involved levels.\n* Women who are or intend to become pregnant within the next 12 months.\n* To treat conditions in which general bone grafting is not advisable.\n* In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).\n* In case of significant vascular impairment proximal to the graft site.\n* In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage \\>4 renal disease or Paget's Disease) that affect bone or wound healing.\n* In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).\n* When intraoperative soft tissue coverage is not planned or possible.\n* Receiving treatment with medication interfering with calcium metabolism.\n* Has degenerative disc disease (DDD) related to a benign or malignant tumor.\n* Has history or presence of active malignancy.\n* Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.\n* Is involved in active litigation relating to his\u002Fher spinal condition.\n* Has participated in an investigational study within 30 days prior to surgery for study devices.",{"count":86,"type":21},60,[60],"This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.\n\nIn this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.",[90,27,91],"Degenerative Disc Disease","Back Pain",[90,27],"2026-03-18",{"date":95,"type":39},"2026-03-20",{"date":97,"type":39},"2024-12-06",{"date":99,"type":21},"2027-08-30",{"name":101,"class":102},"Kuros Biosurgery AG","INDUSTRY",6,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100442175","magnetos-flex-matrix-compared-to-trinity-elite-mixed-with-local-autograft-in-patients-undergoing-up-to-four-level-instrumented-posterolateral-fusion-100442175","NCT05037968","MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion","A Prospective, Randomized, Multi-center Study to Assess the Performance of MagnEtOs Flex Matrix Mixed With Local Autograft Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented poSterolatEral Lumbar\u002FThoraco-lumbar Fusion (PLF)","PRECISE","Inclusion Criteria:\n\n* Patient is able to read\u002Fbe read, understand, and provide written informed consent and has signed the Investigational Review Board (IRB) approved informed consent.\n* Male or female patient ≥ 18 years old.\n* Patients with leg pain, and\u002For back pain requiring up to four-level instrumented posterolateral lumbar\u002Fthoraco-lumbar fusion (T11 - S1)\n* Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment.\n\nExclusion Criteria:\n\n* Requires \\> four-level fusion or expected to need secondary intervention within one year following surgery.\n* Had prior PLF fusion or attempted PLF fusion at the involved levels\n* Had previous decompression at the involved levels.\n* Women who are or intend to become pregnant within the next 12 months\n* To treat conditions in which general bone grafting is not advisable.\n* In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g., defect site stabilization is not possible).\n* In case of significant vascular impairment proximal to the graft site.\n* In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta or Paget's Disease) that affect bone or wound healing.\n* In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).\n* When intraoperative soft tissue coverage is not planned or possible.\n* Receiving treatment with medication interfering with calcium metabolism.\n* Had leg pain, and\u002For back pain related to a benign or malignant tumor.\n* Had history or presence of active malignancy.\n* Has known substance abuse, psychiatric disorder, or condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.\n* Is involved in active litigation relating to his\u002Fher spinal condition.\n* Has participated in an investigational study within 30 days prior to surgery for study devices.",{"count":113,"type":21},100,[60],"This is a phase IV post-marketing study for MagnetOs Flex Matrix. MagnetOs Flex Matrix is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease and undergoing spinal fusion surgery.\n\nIn this study, MagnetOs Flex Matrix will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.\n\nTrinity Elite will also be used according to its latest IFU approved in the US. Specifically, this cellular based allograft is an allograft intended for the treatment of musculoskeletal defects.",[90,27,117],"Leg Pain and\u002For Back Pain",[90,27],"2026-02-23",{"date":121,"type":39},"2026-02-25",{"date":123,"type":39},"2024-06-10",{"date":125,"type":21},"2026-12",{"name":101,"class":102},7,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":151,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":47},"100609711","trans-auricular-stimulation-for-postoperative-inflammation-in-spine-surgery-100609711","NCT07218133","Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery","TAPIS","Inclusion Criteria:\n\n* Long-segment spinal fusions (defined as constructs spanning at least L2-pelvis for thoracolumbar fusions or C2-T2 for cervical fusions)\n* Ability to undergo a reliable neurologic examination and pain assessments\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Shorter-segment spinal fusions than those described above\n* Undergoing current active cancer therapy\n* Undergoing treatment with immunosuppressive drugs\n* Additional spinal surgery within past 6 months\n* Sustained bradycardia or presence of pacemaker\n* History of substance abuse",{"count":136,"type":21},50,[60],"This study is a randomized controlled trial that will evaluate the effect of non-invasive auricular vagal nerve stimulation on inflammatory markers, glycemic control, postoperative pain, and inflammation-related clinical outcomes after long-segment spinal fusion surgeries when compared to current accepted management.",[140,141,142,143,144,145,146,147,148,149,150,27],"Spinal Fusion","Hyperglycemia","Postoperative Pain Management","Postoperative Care","Spine Disease","Neurologic Deficits","Neurological Disorder","Inflammation","Spine Condition","Spinal (Fusion) Surgery","Cytokine Levels",[152,153,154,155,156,157,158,159],"spinal fusion","postoperative pain","glycemic control","inflammation","vagal nerve stimulation","postoperative complications","cytokine","spine surgery","2026-02-17",{"date":162,"type":39},"2026-02-20",{"date":164,"type":39},"2025-10-08",{"date":125,"type":21},{"name":167,"class":46},"Alexander T. Yahanda",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":47},"100608247","rate-of-bone-union-after-surgery-with-stand-alone-fibergraft-100608247","NCT07199075","Rate of Bone Union After Surgery With Stand-alone Fibergraft","Fusion Rate of Anterior Lumbar Interbody Fusion and Extreme Lateral Interbody Fusion Using Titanium Cages Filled With Stand-alone Fibergraft in Lumbar Spinal Fusion","Fibergraft","Inclusion Criteria:\n\n* Adults ≥ 18 years old\n* Diagnosed with the following lumbar spine disorders: foraminal nerve root compression, isthmic spondylolisthesis, and short-segment (1-2 levels) deformity.\n* Undergone primary surgery of ALIF or XLIF using titanium cages filled with standalone Fibergraft and with the following criteria fulfilled (ie, the index surgery):\n\n  * ALIF (up to 2 levels) as either standalone (ie, no posterior procedure) or as an anterior first procedure with posterior procedure as a second procedure.\n  * XLIF (up to 2 levels) as an anterior first procedure with posterior procedure as a second procedure.\n* Consenting to have CT scans taken to allow assessment of fusion status at 12-24 months post index surgery\n\n  * This criterion is applicable to patients who have not undergone revision surgery.\n  * For patients who have undergone revision surgery due to any reason other than nonunion, which typically occurs within 1 year of the index surgery, this criterion is only applicable if it is possible to obtain the CT scan within 12-24 months of the index surgery. If no CT scan can be taken during this window, the patient does not need to undergo the CT scan; in such cases, the CT scan that has been taken as part of the standard of care before the revision surgery will be retrospectively retrieved to assess the fusion status at the time of the revision surgery.\n  * This criterion is not applicable to patients who underwent revision surgery due to nonunion, which typically occurs 1 year after the index surgery; these patients do not need to undergo the CT scan. In such cases, the CT scan that has been taken as part of the standard of care before the revision surgery will also be retrospectively retrieved to assess and grade the fusion status at the time of the revision surgery.\n* Ability to provide informed consent according to the IRB\u002FEC defined and approved procedures\n\nExclusion Criteria:\n\n* Revision surgery\n* Standalone XLIF\n* Posterior lumbar interbody fusion\n* Diagnosis of fractures, malignancies, ankylosing spondylitis, or acute cauda equina syndrome\n* Diagnosis of Parkinson's disease\n* Body mass index \\> 35kg\u002Fm2",{"count":177,"type":21},80,"OBSERVATIONAL","Some people have back problems caused by degenerative conditions or instability of the spine (eg. Spondylolisthesis). These problems can lead to pain, nerve issues, or difficulties in walking. A common treatment is a type of back surgery called lumbar interbody fusion, which helps stabilize the spine.\n\nAt the St. Maartenskliniek in the Netherlands, doctors have been using a special material called Fibergraft Bioactive Glass Putty for such surgeries since 2023. This material helps bones grow and heal, and it's placed inside the spine without needing extra bone from another part of the body.\n\nThis study will look at how well this material works by evaluating how many patients' bones successfully healed after surgery using this material. It will also look at how patients feel and recover after the procedure",[181,182,183,27,184,185,186],"Spine Degeneration","Spine Disorder","Spine Pain","Spine Fusion for Degenerative Spine Disease","Nerve Root Compress;Lumbosac","Spondylolisthesis","NOT_YET_RECRUITING","2025-09-22",{"date":190,"type":39},"2025-09-30",{"date":192,"type":21},"2025-10-31",{"date":194,"type":21},"2026-05-30",{"name":196,"class":46},"AO Innovation Translation Center",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":215,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":47},"100591026","phase-4-effect-of-magnesium-on-neuromonitoring-100591026","NCT06975072","Effect of Magnesium on Neuromonitoring","Pharmacokinetics and Impact of Magnesium Sulfate on Neuromonitoring in Spinal Surgery","MgNm","Inclusion Criteria:\n\nAdult patients (\\>18 years of age) undergoing open thoracolumbar fusion with planned neuromonitoring\n\nExclusion Criteria:\n\n1. Patients with a history of significant cardiac disease (LVEF \\\u003C35%, 2nd\u002F3rd-degree block without a pacemaker, or significant arrhythmia)\n2. Patients with kidney disease (GFR \\\u003C30), or hepatic dysfunction (history of cirrhosis)\n3. Allergy or sensitivity to magnesium\n4. Patient with neuromuscular disease such as myasthenia graves",{"count":206,"type":21},20,[24],"Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Transcranial Motor Evoked Potentials (TcMEPs) monitor the integrity of the motor pathways and are one of the most commonly used monitoring modalities in spinal surgery. Because inhaled anesthetics can negatively affect the ability to monitor TcMEPs, anesthesiologists commonly use a combination of propofol and opioids to maintain the anesthetic state. Additionally, anesthesiologists will frequently administer intravenous infusions of medications that can decrease postoperative pain and opioid use (called opioid-sparing adjuncts) because spinal surgeries result in significant postoperative pain. Despite the increasing use of these agents, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. Magnesium (Mg), a N-methyl-d-aspartate receptors (NMDA) receptor antagonist, is one of the adjuncts with robust data supporting clinical efficacy to decrease pain and opioid use on TcMEPs. Mg has been used clinically for decades. The investigators commonly utilize intravenous magnesium as a component of our spinal anesthesia protocol. However, there is only a single case report that discusses the effects of Mg on TcMEPs. Here the investigators propose a prospective clinical trial to quantitatively assess the effects of various Mg plasma levels on TcMEPs. There is a lack of literature on the pharmacokinetics of magnesium in non-pregnant patients.",[210,211,212,213,214,27],"Spine","Pain","Spine Surgery","Spine Surgery With Neuromonitoring","Spine Surgery With Motor Evoked Potential Monitoring",[216,159,217,218,219,220],"spine","spine fusion","magnesium","neuromonitoring","motor evoked potential monitoring","2025-07-02",{"date":223,"type":39},"2025-07-08",{"date":225,"type":39},"2025-07-01",{"date":227,"type":21},"2026-04-30",{"name":229,"class":46},"University of California, San Francisco",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":47},"100526913","phase-3-effect-of-ketamine-on-intraoperative-motor-evoked-potentials-100526913","NCT06140927","Effect of Ketamine on Intraoperative Motor Evoked Potentials","Inclusion Criteria:\n\n* Adult patients (\\>18 years of age) undergoing posterior spinal fusions.\n\nExclusion Criteria:\n\n* Sensitivity or allergy to ketamine.\n* Schizophrenia or other psychotic conditions\n* Uncontrolled hypertension with systolic blood pressure greater than 180 mmHg\n* Myocardial Infarction\n* Large vascular aneurysms\n* Patients on ketamine as outpatient therapy.","100 Years",{"count":206,"type":21},[239],"PHASE3","The goal of this clinical trial is to learn about the effect of ketamine on intraoperative motor evoked potentials in adult patients undergoing thoracolumbar spinal fusions. Participants will undergo a standard anesthetic. In addition to the standard anesthetic, the patients will be administered increasing doses of ketamine with motor-evoked potentials being measured at each dose, to assess any impacts.",[27,242,243],"Spine Tumor","Spinal Stenosis","2025-05-05",{"date":246,"type":39},"2025-05-07",{"date":248,"type":39},"2023-12-01",{"date":250,"type":21},"2026-12-01",{"name":229,"class":46},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100560686","spine-surgery-video-observation-study-the-creation-of-a-benchmark-video-rgb-depth-dataset-to-investigate-the-feasibility-of-developing-a-markerless-tracking-system-for-spine-surgery-100560686","NCT06580379","Spine Surgery Video Observation Study. The Creation of a Benchmark Video (RGB-Depth) Dataset to Investigate the Feasibility of Developing a Markerless Tracking System for Spine Surgery.","SPIVOS","Inclusion Criteria:\n\n* Candidate surgeries include all spine surgeries taking a posterior approach. This includes both 'open' and 'minimally invasive' surgeries, provided some portion of vertebrae bone is exposed.\n\nExclusion Criteria:\n\n* Candidate surgeries will be excluded if the patient is under the age of 18 or the clinical lead feels the patient lacks capacity to consent.",{"count":260,"type":21},25,"The primary study objective is to build a video dataset, consisting of both colour and depth information, of spine surgery that includes both 'open' and 'minimally invasive' (MIS) surgeries. Using accompanying preoperative CT scans of the patient's spine, we aim to develop a markerless tracking system for spine surgery, which the collected dataset will be used to both train, and then benchmark against.",[27,263,181,264],"Spine Injury","Navigation, Spatial",[266,267,212,268],"Imaging","Depth Imaging","Intraoperative Registration","2024-08-28",{"date":271,"type":39},"2024-08-30",{"date":273,"type":21},"2024-10",{"date":275,"type":21},"2027-10",{"name":277,"class":46},"Imperial College London",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":285,"sex":16,"minAge":286,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":47},"100406163","phase-4-steroids-after-spine-fusion-surgery-100406163","NCT04568837","Steroids After Spine Fusion Surgery","Postoperative Steroids and Recovery After Spine Fusion","Inclusion Criteria:\n\n* All patients over the age of 50 undergoing thoracic and\u002For lumbar fusion with a Spine Center surgeon will be included\n\nExclusion Criteria:\n\n* Patient is already taking chronic steroids\n* Patient is pregnant\n* Patient is decisionally impaired\n* Patient is a prisoner",true,"50 Years",{"count":288,"type":21},420,[24],"This trial studies how well low-dose postoperative corticosteroids (FDA approved) affect patient outcomes (patient reported outcomes, pain medication use, length of stay, major complications, and time to first bowel movement) after thoracic and\u002For lumbar spine fusion surgery.",[27],"2024-04-18",{"date":294,"type":39},"2024-04-22",{"date":296,"type":21},"2025-03-01",{"date":298,"type":21},"2026-10-06",{"name":300,"class":46},"Oregon Health and Science University"]